Back to top

vaccines: Archive

Zacks Equity Research

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Sundeep Ganoria

Should You Buy Moderna Stock Ahead of Q3 Earnings Report?

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

GSKPositive Net Change JNJPositive Net Change VIRNegative Net Change

Shaun Pruitt

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?

Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).

PFEPositive Net Change MTSRPositive Net Change NVONegative Net Change LLYPositive Net Change

Sundeep Ganoria

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.

MRKPositive Net Change MRNAPositive Net Change SMMTPositive Net Change

Sundeep Ganoria

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change